SEC Comment Letter 0000000000-26-006372 to Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: June 25, 2026 · CIK: 0001645460 · Accession: 0000000000-26-006372
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296896
Letter
June 25, 2026 Shao-Lee Lin President and Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135 Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed June 18, 2026 File No. 333-296896 Dear Shao-Lee Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson, Esq.
Show Raw Text
June 25, 2026 Shao-Lee Lin President and Chief Executive Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135 Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed June 18, 2026 File No. 333-296896 Dear Shao-Lee Lin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney M.W. Tygesson, Esq.